Laurence Albigès, MD, PhD, Describes Population With Advanced RCC Receiving Nivolumab Plus Ipilimumab in the CheckMate-214 Trial

Video

Laurence Albigès, MD, PhD, speaks to the patient population included in the phase 3 CheckMate 214 trial, assessing nivolumab plus ipilimumab in patients with treatment-naïve advanced or metastatic renal cell carcinoma.

In an interview with CancerNetwork® during the 2022 Genitourinary Cancers Symposium, Laurence Albigès, MD, PhD, a medical oncologist and head of the Genitourinary Unit at Gustave Roussy in Villejuif, discussed the patient population included in the phase 3 CheckMate 214 trial (NCT02231749).

The trial, which assessed the use of nivolumab (Opdivo) plus ipilimumab (Yervoy) in patients with treatment-naïve advanced or metastatic renal cell carcinoma (RCC), enrolled patients with International Metastatic RCC Database Consortium (IMDC) intermediate- and poor-risk disease with at least 1 poor prognostic feature, according to Albigès.

Transcript:

The CheckMate 214 trial looked at patients with RCC who had metastatic disease that required first-line treatment. These patients could have any disease progression, either locally or at a metastatic level, and were not eligible for surgery but required systemic treatment. What is important in this trial is that the focus for the analysis is on the IMDC intermediate- and poor-[risk] patient population. These are patients who had at least 1 poor prognostic feature among 6 criteria that compose the IMDC classification. Overall, the [intent-to-treat] population in this trial also enrolled patients with [favorable]-risk disease. Nevertheless, the primary end point analysis was in the intermediate- or poor-risk population, which broadly accounted for 80% of our patient population.

Reference

Tannir NM, Signoretti S, Choueiri TK, et al. Efficacy and safety of nivolumab plus ipilimumab (N+I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up. J Clin Oncol. 2022;40(suppl 6):352. doi:10.1200/JCO.2022.40.6_suppl.352

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Related Content